Biogen Inc. (BIIB)

Biogen Inc. (NASDAQ:BIIB) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, it was reported that Biogen is scaling back Apellis Pharmaceuticals’ research pipeline and reducing its R&D staff, weeks after completing a $5.6 billion acquisition of the company.

Jay Woods recommended investing in the BioTech ETF and Biogen in particular within the ETF.

Biogen stock has delivered a strong 57.5% return over the past year, yet the broader valuation checks suggest the shares now look closer to fairly priced than clearly cheap. Over the last 12 months, Biogen has returned 57.5%, which puts more pressure on today’s buyers to justify the higher ...

Calendar & Research Financial Calendar Earnings Calendar & Reports Analyst Ratings Fund Letters Archive Transcripts Search Stock Market Holidays ... Chat Support Create a ticket User Engagement Meeting Status Take Survey Onboarding Tour Give us your feedback ... On July 06, 2026, Biogen Inc BIIB ...

Why Biogen’s AAIC 2026 data drop matters for the stock Biogen (BIIB) is in focus as it prepares to share detailed diranersen Phase 2 results and new LEQEMBI real-world evidence at the Alzheimer’s Association International Conference in London in mid July.